Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias

Osita Okafor, MB ChB; Abbasin Zegard, MB ChB; Peter van Dam, PhD; Berthold Stegemann, PhD; Tian Qiu, PhD; Howard Marshall, MD; Francisco Leyva, MD

Background—Predicting clinical outcomes after cardiac resynchronization therapy (CRT) and its optimization remain a challenge. We sought to determine whether pre- and postimplantation QRS area (QRSarea) predict clinical outcomes after CRT.

Methods and Results—In this retrospective study, QRSarea, derived from pre- and postimplantation vectorcardiography, were assessed in relation to the primary end point of cardiac mortality after CRT with or without defibrillation. Other end points included total mortality, total mortality or heart failure (HF) hospitalization, total mortality or major adverse cardiac events, and the arrhythmic end point. In patients (n=380, age 72.0±12.4 years, 68.7% male) undergoing CRT over 7.7 years (median follow-up: 3.8 years [interquartile range 2.3–5.3]), preimplantation QRSarea ≥102 µVs predicted cardiac mortality (HR: 0.36; P<0.001), independent of QRS duration (QRSd) and morphology (P=0.001). A QRSarea reduction ≥45 µVs after CRT predicted cardiac mortality (HR: 0.19), total mortality (HR: 0.50), total mortality or heart failure hospitalization (HR: 0.44), total mortality or major adverse cardiac events (HR: 0.43) (all P<0.001) and the arrhythmic end point (HR: 0.26; P<0.001). A concomitant reduction in QRSarea and QRSd was associated with the lowest risk of cardiac mortality and the arrhythmic end point (both HR: 0.12, P<0.001).

Conclusions—Pre-implantation QRSarea, derived from vectorcardiography, was superior to QRSd and QRS morphology in predicting cardiac mortality after CRT. A postimplant reduction in both QRSarea and QRSd was associated with the best outcomes, including the arrhythmic end point. (J Am Heart Assoc. 2019;8:e013539. DOI: 10.1161/JAHA.119.013539.)

Key Words: cardiac resynchronization therapy • left bundle branch block • QRS area • QRS duration • vectorcardiography

Cardiac resynchronization therapy (CRT) is an established treatment for patients with heart failure (HF), impaired left ventricular (LV) function, and a wide QRS complex.1 As with any medical therapy, its treatment effect is variable. “Nonresponder” rates range from 9% to 68%, depending on the criteria used to define response.2 Although no medical therapy can be expected to be 100% effective, there is a consensus view that response to CRT can be improved.3

Manifold imaging studies explored mechanical dyssynchrony in relation to patient selection and optimization but, ultimately, no single measure of mechanical dyssynchrony has been adopted by clinical guidelines.4 In this context, we should consider CRT as an electrical treatment and that its substrate should be electrical rather than mechanical. In this respect, QRS duration (QRSd) has been adopted as a surrogate of electrical dyssynchrony in randomized, controlled trials,1 and a reduction in QRSd has been shown to predict better long-term outcomes after CRT.5,6 Evidence has recently emerged in support of vectorcardiography in the field of CRT. In this respect, QRS area (QRSarea) has been shown to correlate with LV lateral wall activation time,7 the maximum rate of rise of LV pressure (∆LV dP/dtmax),8,9 and LV reverse remodeling10 after CRT. Crucially, pre-implantation QRSarea has also been shown to be superior to pre-implantation QRSd and QRS morphology in predicting total mortality after CRT.11,12 Although QRSarea and QRSd duration relate to depolarization in a global sense, QRSarea also yields the dominant axis of the activation sequence.13 Given that the objective of CRT is...
to make depolarization more synchronous, both the pacing location and timing between LV and right ventricular pacing can be used to manipulate activation sequence. In this study, we explored pre- and postimplantation QRS area and QRS duration in relation to long-term cardiac mortality, HF hospitalization, and major adverse cardiac events (MACEs) after CRT.

**Methods**

Patients referred for CRT implantation at the University Hospitals Birmingham, Queen Elizabeth, United Kingdom, were retrospectively evaluated. The study was approved by the local Ethics Committee and local Clinical Audit Department, both of which waived patient consent on the basis that all study tests and interventions had already been undertaken. The study conforms with the Declaration of Helsinki.

**Study Population**

Patients undergoing CRT implantation from November 2011 to June 2018 were identified. Implantation practice adhered to the United Kingdom’s National Institute of Clinical Excellence guidelines, which before 2007 recommended CRT with defibrillation (CRFT-D) only in the context of secondary prevention. After 2014, National Institute of Clinical Excellence recommended cardiac resynchronization therapy with defibrillation rather than CRT-pacing in nonischemic cardiomyopathy.14

Inclusion criteria were the following: indications for CRT according to National Institute of Clinical Excellence guidance and availability of a digitizable 12-lead ECG before and after implantation. Exclusion criteria were the following: subjects with technically unsuitable ECGs and patients with congenital heart disease.

**Device Therapy**

Device implantation was undertaken using standard transvenous techniques with patients under local anesthesia and

**Clinical Perspective**

*What Is New?*

- Pre-implantation QRS area was superior to QRS duration and QRS morphology in predicting cardiac and total mortality after cardiac resynchronization therapy.
- Concomitant reductions in QRS area and QRS duration after cardiac resynchronization therapy were associated with the best survival and the lowest risk of heart failure hospitalization, major adverse cardiac events as well as ventricular arrhythmias.

*What Are the Clinical Implications?*

- Reductions in QRS area and QRS duration could be a focus for optimization after cardiac resynchronization therapy implantation.

**Figure 1.** Vectorcardiography in cardiac resynchronization therapy. The vectorcardiogram displays the various features of the ECG, such as the QRS complex, in the form of “loops,” which are determined from vectors representing successive, instantaneous mean electrical forces throughout the cardiac cycle. A, A representation of the 3 vectorcardiogram leads (X, Y, and Z), according to Frank’s orthogonal lead system. B, Two-dimensional vector loops in the frontal (X-Y leads), sagittal (Y-Z leads), and transverse (X-Z leads) planes from a patient with a left bundle branch block. The QRS area is calculated as the integral sum of the area bound by the QRS complex and the isoelectric baseline in each vectorcardiogram lead (X, Y, and Z).
Table 1. Characteristics of the Study Group According to Pre-Implantation QRS Area

| Characteristic                          | All | QRS<sub>area ≥102 lV/s</sub> | QRS<sub>area <102 lV/s</sub> | P Value |
|----------------------------------------|-----|------------------------------|------------------------------|---------|
| N                                      | 380 | 197                          | 183                          |         |
| Age, y                                 | 72±12.4 | 72.2±12.9                  | 71.9±11.7                    | 0.832   |
| Sex (male), n (%)                      | 261 (68.68) | 119 (60.41)               | 142 (77.6)                   | <0.001  |
| NYHA class, n (%)                      |     |                              |                              |         |
| I                                      | 26 (7.34) | 17 (9.34)                  | 9 (5.23)                     | 0.190   |
| II                                     | 87 (24.58) | 46 (25.27)                | 41 (23.84)                   |         |
| III                                    | 225 (63.56) | 114 (62.64)             | 111 (64.53)                  |         |
| IV                                     | 16 (4.52) | 5 (2.75)                   | 11 (6.4)                     |         |
| Cause, n (%)                           |     |                              |                              |         |
| Ischemic                               | 182 (47.89) | 74 (37.56)               | 108 (59.02)                  | <0.001  |
| Nonischemic                            | 198 (52.11) | 123 (62.44)              | 75 (40.98)                   |         |
| Comorbidities, n (%)                   |     |                              |                              |         |
| Diabetes mellitus                      | 89 (23.42) | 41 (20.81)                | 48 (26.23)                   | 0.213   |
| Hypertension                           | 106 (27.89) | 57 (28.93)                | 49 (26.78)                   | 0.639   |
| CABG                                   | 64 (16.84) | 23 (11.68)                | 41 (22.4)                    | 0.005   |
| Device type, n (%)                     |     |                              |                              |         |
| CRT-D                                  | 209 (55.15) | 94 (47.96)               | 115 (62.84)                  | 0.004   |
| CRT-P                                  | 170 (44.85) | 102 (52.04)              | 68 (37.16)                   |         |
| Upgrades, n (%)                        |     |                              |                              |         |
| Pacemaker to CRT-D                     | 39 (47.56) | 23 (43.40)                | 16 (55.17)                   | 0.307   |
| Pacemaker to CRT-P                     | 43 (52.44) | 30 (56.60)                | 13 (44.83)                   |         |
| CRT-D indication*                      |     |                              |                              |         |
| Primary prevention                     | 166 (79.4) | 76 (80.9)                 | 90 (78.3)                    | 0.645   |
| Secondary prevention                   | 43 (20.6) | 18 (19.1)                 | 25 (21.7)                    |         |
| LVEF, %                                | 25.8±9.9 | 25.5±9.7                  | 26.0±10.3                    | 0.633   |
| Medication, n (%)                      |     |                              |                              |         |
| ACEI/ARA                               | 337 (89.63) | 173 (88.72)              | 164 (90.61)                  | 0.548   |
| β-Blocker                              | 277 (73.67) | 140 (71.79)              | 137 (75.69)                  | 0.391   |
| MRA                                    | 167 (44.41) | 80 (41.03)               | 87 (48.07)                   | 0.170   |
| ECG variables                           |     |                              |                              |         |
| Sinus rhythm, n (%)                    | 269 (70.79) | 152 (77.16)              | 117 (63.93)                  | 0.005   |
| AF/flutter, n (%)                      | 111 (29.21) | 45 (22.84)               | 66 (36.07)                   |         |
| PR interval, ms                        | 192.5±54.7 | 181.6±39.8               | 207.5±67.5                   | <0.001  |
| QRS<sub>d</sub>, ms                    | 153.5±22.7 | 163.9±20.4               | 142.2±19.5                   | <0.001  |
| QRS <150 ms, n (%)                     | 169 (44.7) | 45 (22.84)               | 124 (67.76)                  | <0.001  |
| LBBB, n (%)                            | 239 (62.89) | 151 (76.65)              | 88 (48.09)                   | <0.001  |
| RBBB, n (%)                            | 33 (8.68) | 1 (0.51)                  | 32 (17.49)                   | <0.001  |
| NICD, n (%)                            | 59 (15.53) | 5 (2.54)                  | 54 (29.51)                   | <0.001  |
| RV-paced, n (%)                        | 49 (12.89) | 40 (20.30)               | 9 (4.92)                     | <0.001  |
| Vectorcardiography variable            |     |                              |                              |         |
| QRS<sub>area ≥102 lV/s</sub>          | 113.4±56.5 | 156.9±41.7               | 66.6±22.7                    | <0.001  |

ACEI indicates angiotensin receptor converting enzyme inhibitor; AF, atrial fibrillation; ARA, angiotensin receptor antagonist; CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy with defibrillation; CRT-P, cardiac resynchronization therapy-pacing; LBBB, left bundle branch block; MRA, mineralocorticoid receptor antagonist; LVEF, left ventricular ejection fraction; NICD, nonspecific conduction delay; NYHA, New York Heart Association; QRS<sub>area ≥102 lV/s</sub>, QRS area; QRS<sub>d</sub>, QRS duration; RBBB, right bundle branch block; RV, right ventricular.

*Expressed as a percentage of CRT-D devices.
intravenous sedation. Following implantation, patients were followed up in combined cardiac device therapy/HF clinics. Devices were programmed according to physician discretion. Generally, backup atrial pacing was set at 60 beats/min, and the pacing mode was set to DDDR. The atrioventricular delay was set at 90 ms and the interventricular delay to between 0 and 20 ms (LV first). In patients in permanent atrial fibrillation, right ventricular and LV leads were deployed, a CRT generator was implanted, and devices were programmed to a ventricular triggered mode. Atrioventricular junction ablation was undertaken according to physicians’ discretion. Targeted echocardiographic optimization was only undertaken in symptomatic nonresponders.

**Table 2. Clinical Outcomes**

|                          | Pre-CRT | Post-CRT |
|--------------------------|---------|----------|
|                          | N       | QRSarea ≥102 μVs | QRSarea <102 μVs | QRSarea Reduction ≥45 μVs | QRSarea Reduction <45 μVs |
| Mortality end points     |         |            |              |                |                          |
| Cardiac mortality        | 70 (18.4) | 21 (10.7) | 49 (26.8) | 11 (6.21) | 59 (29.1) |
| Sudden cardiac death*    | 5 (7.14) | 1 (4.76) | 4 (8.16) | 0 | 5 (8.47) |
| Death from pump failure* | 63 (90.0) | 19 (90.5) | 44 (89.8) | 10 (90.9) | 53 (89.8) |
| Total mortality          | 135 (35.5) | 55 (27.9) | 80 (43.7) | 42 (23.7) | 93 (45.8) |
| Total mortality or HF hospitalization | 165 (43.4) | 66 (33.5) | 99 (54.1) | 53 (29.9) | 112 (55.2) |
| Total mortality or hospitalization for MACE | 185 (48.7) | 74 (37.6) | 111 (60.7) | 59 (33.3) | 126 (62.1) |
| Ventricular arrhythmic events |         |            |              |                |                          |
| All VT/VF                | 32 (8.42) | 12 (6.09) | 20 (10.9) | 7 (3.95) | 25 (12.3) |
| VT/VF treated with ATP only | 6 (15.8) | 4 (2.03) | 2 (1.09) | 3 (1.69) | 3 (1.48) |
| Appropriate shocks (with or without ATP) | 19 (5.0) | 7 (3.55) | 14 (7.65) | 2 (1.13) | 17 (8.37) |
| Inappropriate shocks      | 1 (0.26) | 0 | 1 (0.5) | 0 | 1 (0.5) |

Clinical outcomes, expressed as n (%), according to pre-implantation QRS area (QRSarea) and postimplantation change in QRSarea. ATP indicates antitachycardia pacing; CRT, cardiac resynchronization therapy; HF, heart failure; MACE, major adverse cardiac events; VF, ventricular fibrillation; VT, ventricular tachycardia.

*Expressed as a percentage of cardiac deaths.

intravenous sedation. Following implantation, patients were followed up in combined cardiac device therapy/HF clinics. Devices were programmed according to physician discretion. Generally, backup atrial pacing was set at 60 beats/min, and the pacing mode was set to DDDR. The atrioventricular delay was set at 90 ms and the interventricular delay to between 0 and 20 ms (LV first). In patients in permanent atrial fibrillation, right ventricular and LV leads were deployed, a CRT generator was implanted, and devices were programmed to a ventricular triggered mode. Atrioventricular junction ablation was undertaken according to physicians’ discretion. Targeted echocardiographic optimization was only undertaken in symptomatic nonresponders.

**Lead positions**

The anteroposterior, as well as the left anterior and right anterior oblique fluoroscopic views from coronary sinus venography taken at the time of implantation were used retrospectively to assess the LV lead tip position, as previously described. All LV lead positions were assessed retrospectively by an experienced implanter (F.L.) who was blinded to clinical outcome data.

**ECG**

Pre-implantation, standard supine 12-lead ECGs (25 mm/s, 10 mm/mV) were used for analysis. A left bundle branch block (LBBB) was defined as a QRSd >120 ms, rS or QS in lead V1, notched or slurred R-waves in leads I, aVL, V5 or V6, with absent q waves in leads V3 and V6. We used this definition rather than “strict” Strauss criteria, as the latter is not predictive of clinical outcomes after CRT. Right bundle branch block was defined as a QRS ≥120 ms, with a wide, positive R-wave deflection in lead V1 and a slurred S wave in leads I and V6. A nonspecific intraventricular conduction delay was defined as nonpaced QRS >120 ms not fitting these criteria. Postimplantation ECGs were undertaken within 3 months after implantation.

**Vectorcardiography**

Standard 12-lead ECGs were first converted to an Extensible Markup Language (XML) format using ECGScan (AMPS LLC, New York, USA), a commercially available program approved by the US Food and Drug Administration. A custom-made program was used for generation of 2 vectorcardiographies according to Frank’s orthogonal lead system using the Kors transformation. The latter was used given previous evidence that it is superior to other vectorcardiography transformations in predicting clinical outcomes after CRT. The start and end of the QRS complex were defined semi-automatically using digital calipers at 200% magnification. For paced rhythms, the onset and end of the QRS complex was measured manually, excluding the pacing spike. Digitization of ECGs and generation of vectorcardiographies were undertaken by a single investigator (O.O.) who was blinded to clinical outcomes.
collected by another investigator (A.Z.). The QRS$_{area}$ was calculated as the integral between the ventricular deflection curve and the isoelectric line in each of the 3 orthogonal leads (X, Y, and Z), according to the formula: $(X^2_{area} + Y^2_{area} + Z^2_{area})^{1/2}$ (Figure 1).

**End points**

The primary end point was cardiac mortality, which included cardiac transplantation or implantation of a ventricular assist device. The secondary end point was total mortality. Ancillary end points included total mortality or unplanned HF hospitalization; total mortality or unplanned hospitalization for MACE; and the combined end point of sudden cardiac death, ventricular tachycardia, ventricular fibrillation, or shock. MACE included unplanned hospitalization for HF, myocardial infarction, acute coronary syndrome, ventricular arrhythmias, and atrial fibrillation. A HF hospitalization was defined as an unplanned admission related to worsening dyspnea, in association with peripheral edema, pulmonary edema on chest radiography, and requirement for intravenous diuretic therapy. Device-treated arrhythmias (appropriately treated with shocks or antitachycardia pacing) not leading to an unplanned hospitalization were not regarded as a hospitalization for MACE. Stroke and pulmonary embolism were not regarded as MACE. In composite end points, the first event was included in statistical analyses. Mortality data were collected through medical record and cross-checked with a national mortality database. Data were collected retrospectively from medical records and entered into an electronic database every 6 months by investigators who were blinded to clinical and imaging data. Events were adjudicated by blinded investigators on a 6-monthly basis.

**Mode of death**

Sudden cardiac death was defined as a natural, unexpected death because of cardiac causes, heralded by an abrupt loss of consciousness within 1 hour of the onset of acute symptoms. Death from pump failure was defined as “death after a period of clinical deterioration in signs and symptoms of HF despite medical treatment”.$^{17}$

**Statistical Analysis**

Continuous variables are expressed as mean± SD. Normality was tested using the Shapiro–Wilk test. Comparisons between normally distributed continuous variables were made using the Student $t$ test. Categorical variables were analyzed using $\chi^2$ tests. Receiver operating characteristic curves were

---

**Figure 2.** Receiver-operator characteristic curves. Graphs show areas under the receiver-operator characteristic curves (AUC) for QRSd, QRS area, and QRS morphology (LBBB) in the whole cohort. AUC indicates area under the curve; CRT, cardiac resynchronization therapy; LBBB, left bundle branch block.
created to assess the predicted probabilities of ECG and vectorcardiography variables in relation to cardiac mortality. A 10-fold cross-validation was used as the model validation technique for assessing performance, and the average was calculated over 10 repetitions. The measure with largest area under the receiver operating characteristic (area under the curve [AUC]) was used for subsequent analyses. The Liu method was also applied to estimate nonparametrically the optimal cutoffs for ECG and vectorcardiography measures. Kaplan–Meier curves and the log-rank test were used to assess cumulative survival and Cox proportional hazard models were used to assess relative risks. Proportionality hypotheses were verified by visual examination of log (survival) and Schoenfeld residuals. Variables reaching \( P < 0.10 \) as univariate predictors of cardiac mortality were entered in multivariate models. Statistical analyses were undertaken by a biostatistician (T.O.) who did not partake in data collection. The Stata15 (StataCorp, TX) statistical package was used. The package “cvauroc” was used for cross-validation of the areas under the receiver operating characteristic curve, and package “cutpt” was used for empirical estimation of optimal cutoffs. A 2-sided \( P < 0.05 \) was considered statistically significant.

Results
Baseline Characteristics
The analytic sample consisted of 380 patients. As shown in Table 1, baseline characteristics were typical of a CRT population (age \( 72.0 \pm 12.4 \) years [mean\( \pm SD \)], 68.7% male) with a left ventricular ejection fraction of \( 25.8 \pm 9.9\% \) and a 

Figure 3. Clinical outcomes according to pre-implantation QRS area. Kaplan–Meier survival curves for the various end points according to precardiac resynchronization therapy QRS\(_{area}\). Results of univariate Cox proportional hazard models are expressed in terms of hazard ratio (HR) (95% CI). HF indicates heart failure; MACE, major adverse cardiac events.
QRS Area and CRT

Univariable Analyses of Predictors of Clinical Outcomes After CRT

|                      | Total Mortality or HF Hospitalization | Total Mortality | Total Mortality or MACE |
|----------------------|--------------------------------------|----------------|-------------------------|
|                      | HR                                   | 95% CI         | P-Value                 | HR                                   | 95% CI         | P-Value                 | HR                                   | 95% CI         | P-Value                 |
| QRSd [≥150 ms]       | 0.33                                 | 0.19–0.57      | <0.001                 | 0.50                    | 0.39–0.76                              | <0.001         | 0.53                    | 0.39–0.75                              | <0.001         | 0.66                    |<0.001 |
| QRS area [≥102 lVs]  | 1.02                                 | 1.01–1.03      | 0.001                  | 1.01                    | 1.01–1.02                              | 0.001         | 1.01                    | 1.01–1.02                              | 0.001         | 1.01                    |<0.001 |
| QRS area reduction ≥45 lVs | 0.19                          | 0.10–0.36       | <0.001                 | 0.45                    | 0.31–0.65                              | <0.001         | 0.44                    | 0.32–0.61                              | <0.001         | 0.43                    |<0.001 |
| QRSd reduction*     | 0.23                                 | 0.14–0.43      | <0.001                 | 0.51                    | 0.35–0.75                              | <0.001         | 0.48                    | 0.35–0.75                              | <0.001         | 0.48                    |<0.001 |

Results of univariate Cox proportional hazards models, expressed as hazard ratio (HR) and 95% CI, for QRS area (QRSarea) and QRS duration (QRSd) using specified cutoffs (in parentheses), and for QRS morphology (LBBB). Results of analyses with QRS area reduction ≥45 lVs and QRSd reduction ≥45 ms are not shown (HR: 1.00 [95% CI: 0.99–1.01], P=0.92; HR: 1.00 [95% CI: 0.99–1.01], P=0.80 respectively). Refers to any QRSd reduction below baseline.

Pre-CRT QRS area

Over a median follow-up period of 3.8 years (interquartile range 2.3–5.3), 135/380 (36%) patients died, 70/380 (18%) from cardiac causes and 31/380 (8%) from noncardiac causes (Table 2). The cause of death was unknown in 34/380 (9%).

The AUC for predicting cardiac mortality was higher for QRS area (all causes of death) than for QRSd or QRS morphology (0.71 [95% CI: 0.69–0.73] versus 0.60 [95% CI: 0.57–0.63] and 0.53 [95% CI: 0.50–0.56], respectively; P<0.001 for comparison) (Figure 2) and for QRS area and QRS morphology combined (AUC: 0.66; P<0.002). In Kaplan–Meier survival analyses, QRS area ≥102 lVs was associated with a lower cardiac mortality (P<0.001), total mortality (P=0.001), total mortality or HF hospitalization, and total mortality or MACE (both P<0.001) (Table 2 and Figure 3). In univariable Cox proportional hazards analyses, QRS area predicted cardiac mortality, total mortality, total mortality or HF hospitalization, and total mortality or MACE (all P<0.001) (Table 3). In multivariable analyses, QRS area (per lVs) predicted cardiac mortality (adjusted hazard ratio [HR]: 0.99 [95% CI: 0.98–0.99], independent of all baseline variables, including QRSd and QRS morphology (Table 4).

Post-CRT QRS area

The QRS area decreased by 41.0 lVs (interquartile range: −79 to −4) after CRT (Figure 4). The cutoff of ΔQRS area derived from Liu method was −45 lVs (−60 to −31 lVs). As shown in Table 5, the ΔQRS area groups were well matched for age, New York Heart Association class, hypertension and diabetes mellitus status, device type, left ventricular ejection fraction, and medical therapy (Table 5). A QRS area reduction ≥45 lVs group had a lower proportion of men (P<0.001), and most had nonischemic cardiomyopathy (P<0.001). As expected from the ΔQRS area grouping, there were significant differences in ECG and vectorcardiography variables. Cardiac mortality was 11/177 (6.21%) in patients with QRS area reduction ≥45 lVs and 59/203 (29.1%) in patients with QRS area reduction <45 lVs (Table 2). The AUC for predicting cardiac mortality for ΔQRS area and ΔQRSd were similar (0.74 versus 0.72; P=0.425 for comparison) (Figure 2).
In Kaplan–Meier survival analyses, a QRS area reduction $\geq 45$ lVs was associated with a lower cardiac mortality, total mortality, or MACE, compared with a QRS area reduction $<45$ lVs (all $P < 0.001$) (Figures 5 and 6). In univariate analyses, a QRS area reduction $\geq 45$ lVs was a strong predictor of cardiac mortality (HR: 0.19, 95% CI: 0.10–0.36), as well as other end points (all $P < 0.001$) (Table 3).

**Interaction of $\Delta$QRS area and $\Delta$QRSd**

As shown in Figures 2 and 5, $\Delta$QRS area and $\Delta$QRSd were comparable predictors of cardiac mortality. In Cox proportional hazard analyses, a significant interaction between $\Delta$QRS area and $\Delta$QRSd emerged with respect to cardiac mortality (HR: 0.12, 96% CI 0.06–0.26). A similar trend was observed for total mortality, total mortality or HF hospitalization, and total mortality or MACE (Figure 6).

**Lead Positions**

Most LV leads were deployed in a lateral or posterolateral position (Table 5). As shown in Figure 7, there was considerable interindividual variability in $\Delta$QRS area and $\Delta$QRSd within each LV lead position, but no significant differences emerged in $\Delta$QRS area or $\Delta$QRSd between the different LV lead positions.

**Arrhythmic events**

As shown in Table 3 and Figure 8, both QRSd and QRS area predicted the combined end point of sudden cardiac death, ventricular tachycardia/ventricular fibrillation or shock, but no

---

**Table 4. Univariate and Multivariate Analysis of Pre-Implantation Variables in Relation to Cardiac Mortality**

|                        | Univariate |          |          |          |          |          |          |          |          |          |
|------------------------|------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|                        | HR         | 95% CI   | $P$ Value| HR       | 95% CI   | $P$ Value|
| Age, y                 | 1.02       | 1.00     | 1.04     | 0.044    | 1.02     | 1.00     | 1.05     | 0.097    |
| Sex (male)             | 2.25       | 1.21     | 4.19     | 0.011    | 1.57     | 0.80     | 3.07     | 0.186    |
| NYHA class (I, II)     | 0.61       | 0.32     | 1.14     | 0.122    |
| Ischemic cause         | 1.73       | 1.07     | 2.80     | 0.026    | 1.07     | 0.63     | 1.80     | 0.813    |

**Comorbidities**

- Diabetes mellitus: 2.08 (1.28–3.38) ($P = 0.003$)
- Hypertension: 1.25 (0.76–2.08) ($P = 0.380$)
- CABG: 1.46 (0.83–2.54) ($P = 0.187$)
- CRT-D: 0.79 (0.49–1.26) ($P = 0.327$)
- Upgrades: 1.18 (0.67–2.09) ($P = 0.564$)
- LVEF (%): 0.98 (0.96–1.01) ($P = 0.141$)

**Medication**

- ACEI/ARA: 0.56 (0.29–1.10) ($P = 0.092$)
- $\beta$-Blocker: 0.80 (0.48–1.33) ($P = 0.389$)
- MRA: 1.24 (0.78–1.98) ($P = 0.371$)

**ECG variables**

- AF/flutter: 1.62 (1.01–2.62) ($P = 0.047$)
- PR interval, ms: 1.00 (1.00–1.01) ($P = 0.153$)
- LBBB: 0.79 (0.49–1.27) ($P = 0.331$)
- RBBB: 2.50 (1.34–4.65) ($P = 0.004$)
- RV-paced: 0.56 (0.22–1.38) ($P = 0.207$)
- NICD: 1.08 (0.58–2.01) ($P = 0.806$)
- QRSd, ms: 0.99 (0.98–1.00) ($P = 0.075$)
- QRS area, lVs: 0.99 (0.98–0.99) ($P < 0.001$)
- NICD: 1.08 (0.58–2.01) ($P = 0.806$)
- QRS area, $\Delta$ lVs: 0.99 (0.98–0.99) ($P < 0.001$)

ACEI indicates angiotensin receptor converting enzyme inhibitor; AF, atrial fibrillation; ARA, angiotensin receptor antagonist; CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy with defibrillation; HR, hazard ratio; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NICD, nonspecific intraventricular conduction delay; NYHA, New York Heart Association; QRS area, QRS area; QRSd, QRS duration; RBBB, right bundle branch block; RV, right ventricular.
such relationship was observed for QRS morphology. A QRSarea reduction $\geq 45$ μVs (HR: 0.26, 95% CI 0.11–0.58) and QRSd reduction (HR: 0.33, 95% CI 0.17–0.67) predicted this combined end point. Concomitant reductions in QRSarea and QRSd were associated with the lowest risk of the arrhythmic end point (HR: 0.12, 95% CI 0.04–0.41).

Discussion

This is the first study to explore both pre- and postimplantation QRSarea in relation to long-term, cause-specific mortality, as well as long-term HF hospitalization, MACE, and ventricular arrhythmias after CRT. Several findings have emerged. First, pre-implantation QRSarea was superior to QRSd and QRS morphology in predicting cardiac mortality after CRT. Second, a QRSarea reduction after CRT was associated with favorable outcomes, independent of baseline QRSd or QRS morphology. Third, the best outcomes after CRT were observed in patients exhibiting concomitant reductions in QRSarea and QRSd.

Pre-CRT QRSarea

This study provides an external validation of the findings of 2 observational studies showing that QRSarea is superior to QRSd and QRS morphology in predicting total mortality after CRT.11,12 We found that QRSarea ($<102$ μVs) predicted total mortality, with an AUC of 0.71, which is higher than the AUC of 0.61 identified by van Stipdonk et al using a cutoff of 109 μVs.11 Emerek et al found that a QRSarea $\leq 95$ μVs was associated with a higher total mortality than a QRSarea $>95$ μVs, with an unadjusted HR of 2.11 ($P<0.001$).12 Using a cutoff of 102 μVs, we have found an unadjusted HR of 1.73 ($P=0.002$) for total mortality and 2.77 for cardiac mortality ($P<0.001$).

Post-CRT $\Delta$QRSarea

In an acute hemodynamic study of 25 patients with LBBB, De Pooter et al showed that $\Delta$QRSarea correlated with $\Delta$LV dP/dtmax.8 This is consistent with our finding that a reduction in QRSarea was associated with a lower cardiac mortality, as well as other end points. While De Pooter et al8 found that $\Delta$QRSarea after CRT was a stronger correlate of $\Delta$LV dP/dtmax than $\Delta$QRSd, we found that both $\Delta$QRSd and $\Delta$QRSarea were comparable in predicting long-term clinical outcomes. Importantly, the combination of $\Delta$QRSd and $\Delta$QRSarea had additive effects in predicting cardiac mortality: patients who exhibited reductions in both variables experienced the best outcomes after CRT, whereas patients who did not exhibit reductions in either experienced the worst outcomes.

QRSd

Randomized, controlled trials of CRT19,20 adopted a QRSd $\geq 120$ ms as an indication for CRT. In COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure), patients without LBBB and those with QRSd $\leq 147$ ms did not derive a benefit.19 Similarly, in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–
Table 5. Characteristics of the Study Group According to Post-Implantation Change in QRS Area

|                          | QRS<sub>area</sub> Reduction ≥45 µVs | QRS<sub>area</sub> Reduction <45 µVs | P Value |
|-------------------------|----------------------------------|----------------------------------|--------|
| N                       | 177                              | 203                              |        |
| Age, y                  | 72.1±13.1                        | 72±11.7                          | 0.979  |
| Sex (male), n (%)       | 103 (58.19)                      | 158 (77.83)                      | <0.001 |
| NYHA class, n (%)       |                                  |                                  |        |
| I                       | 14 (8.48)                        | 12 (6.35)                        | 0.322  |
| II                      | 36 (21.82)                       | 51 (26.98)                       |        |
| III                     | 110 (66.67)                      | 115 (60.65)                      |        |
| IV                      | 5 (3.03)                         | 11 (5.82)                        |        |
| Cause, n (%)            |                                  |                                  |        |
| Ischemic                | 67 (37.85)                       | 115 (56.65)                      | <0.001 |
| Nonischemic             | 110 (62.15)                      | 88 (43.35)                       |        |
| Comorbidities, n (%)    |                                  |                                  |        |
| Diabetes mellitus       | 44 (24.86)                       | 45 (22.17)                       | 0.537  |
| Hypertension            | 50 (28.25)                       | 56 (27.59)                       | 0.886  |
| CABG                    | 17 (9.6)                         | 47 (23.15)                       | <0.001 |
| Device type, n (%)      |                                  |                                  |        |
| CRT-D                   | 90 (51.14)                       | 119 (58.62)                      | 0.144  |
| CRT-P                   | 86 (48.86)                       | 84 (41.38)                       |        |
| Upgrades, n (%)         |                                  |                                  |        |
| Pacemaker to CRT-D      | 14 (35)                          | 25 (59.52)                       | 0.026  |
| Pacemaker to CRT-P      | 26 (65)                          | 17 (40.48)                       |        |
| LVEF                    | 25.3±9.1                         | 26.2±10.7                        | 0.429  |
| Medication, n (%)       |                                  |                                  |        |
| ACEI/ARA                | 154 (88)                         | 183 (91.04)                      | 0.334  |
| β-Blocker               | 125 (71.43)                      | 152 (75.62)                      | 0.357  |
| MRA                     | 82 (46.66)                       | 85 (42.29)                       | 0.374  |
| ECG variables           |                                  |                                  |        |
| Sinus rhythm, n (%)     | 139 (78.53)                      | 130 (64.04)                      | 0.002  |
| AF/flutter, n (%)       | 38 (21.47)                       | 73 (35.96)                       |        |
| PR interval, ms         | 173.3±34.5                       | 208.8±67.6                      | <0.001 |
| QRSd, ms                | 162.1±20.6                       | 145.9±21.8                      | <0.001 |
| LBBB, n (%)             | 134 (75.71)                      | 105 (51.72)                      | <0.001 |
| RBBB, n (%)             | 2 (1.13)                         | 31 (15.27)                       | <0.001 |
| NICD, n (%)             | 10 (5.65)                        | 49 (24.14)                       | <0.001 |
| RV-paced, n (%)         | 31 (17.51)                       | 18 (8.87)                        | 0.012  |
| Vecotcardiography variable |                              |                                  |        |
| QRS<sub>area</sub> µVs  | 153.9±47.5                       | 78.1±36.3                        | <0.001 |

Circumferential lead positions

|                      | QRS<sub>area</sub> µVs | QRS<sub>area</sub> µVs | P Value |
|----------------------|------------------------|------------------------|--------|
| Anterior             | 6 (3.39)               | 8 (3.94)               | 0.498  |
| Anterolateral        | 28 (15.8)              | 37 (18.2)              |        |
| Lateral              | 73 (41.2)              | 86 (42.3)              |        |
| Posterolateral       | 24 (13.6)              | 16 (8.93)              |        |
| Posterior            | 46 (26.0)              | 56 (27.6)              |        |

Cardiac Resynchronization Therapy) trial, patients with a QRSd <150 ms derived no survival benefit from CRT. In the present study, we found that a QRSd ≥150 ms was associated with a lower cardiac mortality, compared with a QRSd <150 ms. The ability of QRSd to predict cardiac mortality, however, was relatively weak (AUC: 0.60).

Meta-analyses of observational studies have shown an inconsistent relationship between post-CRT ΔQRSd and “clinical response.” In these meta-analyses, however, “clinical response” was defined in terms of symptoms, echocardiographic variables, and/or hard end points, assuming that these are identical, interchangeable measures. On the other hand, studies focusing on hard end points do indeed support a relationship between a QRSd reduction and better outcomes after CRT. The REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) study, the only randomized controlled trial to address ΔQRSd after CRT, explored acute ΔQRSd in the CRT-treated group in relation to the primary end point of the clinical composite score, as well as LV reverse remodeling. Although not designed to address hard end points, REVERSE reported an association between ΔQRSd and total mortality or HF hospitalization over a relatively short follow-up (12 months in North America and for 24 months in Europe) on univariate analyses, but not in a multivariate model that corrected for baseline QRSd. Importantly, however, the CRT-treated group in REVERSE only had 4 deaths over 24 months, raising the possible play of statistical underpowering. In contrast, in an observational study, Appert et al showed that a lack of postoperative QRSd reduction was independently associated with an increased risk of total mortality over a median follow-up period of 48 months. In a similar study, Jastrzebski et al showed that a QRSd reduction predicted death from any cause or urgent heart transplantation and death from any cause/urgent heart transplantation or hospital admission for HF over an average follow-up period of 46 months. In the present study, in which 135 deaths occurred over a median follow-up of 3.8 years, a QRSd...
Figure 5. QRS area and QRS duration in relation to cardiac mortality. Kaplan–Meier survival curves and univariate HR and (95% CI) for QRS area (QRS\textsubscript{area}) and QRS duration (QRS\textsubscript{d}) in relation to cardiac mortality. *Refers to the interaction between changes in QRS\textsubscript{area} and QRS\textsubscript{d} after CRT. HR indicates hazard ratios.

DOI: 10.1161/JAHA.119.013539
reduction below baseline predicted cardiac mortality, total mortality, total mortality or HF hospitalization, and total mortality or MACE.

QRS Morphology

Observational studies as well as large registries and subanalyses of randomized, controlled trials have shown that patients with a LBBB morphology derive the most benefit from CRT. While some studies have suggested that a LBBB defined using “strict” criteria, with notching and/or slurring of the QRS complex, is associated with a better left ventricular ejection fraction response to CRT, this is not a consistent finding. Moreover, Emerek et al found that “strict” (Strauss) criteria of LBBB was not predictive of clinical outcomes after CRT. In the present study, a conventionally defined LBBB did not predict cardiac mortality after CRT (AUC: 0.53).

Lead Position

We have observed a considerable interindividual variability in QRS area at a given LV lead position. In this regard, De Pooter et al also found a similar interindividual variability in QRS area in CRT recipients with a LBBB. Crucially, they also found that QRS area and the acute hemodynamic response to CRT in a given patient could be improved by changing the LV lead position. Together, these findings make the case for optimization of QRS area in CRT recipients. To date, however, no studies have prospectively explored this issue.

Arrhythmic events

Several studies have suggested that QRSd predicts sudden cardiac death. In contrast, no studies have explored QRS area or ΔQRS area in relation to sudden cardiac death or ventricular tachycardia/ventricular fibrillation. Although pre-

---

**Figure 6.** Secondary clinical end points according to changes in QRS area and QRS duration. Kaplan–Meier survival curves for the various end points according to postcardiac resynchronization therapy reductions in QRS area (≥45 μVs) QRS duration (QRSd; to any value below baseline). HF indicates heart failure; MACE, major adverse cardiac events.
implantation QRS area did not predict this end point, its reduction was associated with a 74% reduction in the end point. Moreover, concomitant with QRS area reduction, a QRd reduction was associated with an 88% lower risk of the combined end point. This novel finding, which was not anticipated, could speculatively relate to a greater dispersion of depolarization in relation to arrhythmic events. The physiological basis for this empirical finding requires further study.

Clinical Perspectives
Attention has recently focused on ECG imaging using body surface mapping as a tool for identifying electrical dyssynchrony and to predict response to CRT.34,35 Although there is a proof-of-principle and encouraging clinical data to support the use of this technique in CRT, it requires specialized acquisition. Importantly, data on body surface mapping in relation to long-term outcomes after CRT are lacking. In contrast, QRS area can be readily derived from the standard 12-lead ECG and crucially, is now known to predict long-term clinical outcomes. The role of QRS area in patient selection and CRT optimization requires further investigation.

Limitations
This study has all the limitations of an observational study. Although we have corrected for potential confounders using...
Figure 8. Sudden cardiac death and ventricular arrhythmias according to postimplantation changes in QRS area and QRS duration. Kaplan–Meier survival curves for the combined end point of sudden cardiac death (SCD), ventricular tachycardia (VT)/ventricular fibrillation (VF), or shock according to postimplantation reductions in QRS area (QRS\textsubscript{area} \geq 45 \text{ μVs}) QRS duration (QRS\textsubscript{d} to any value below baseline). *Refers to the comparison of the group with concomitant reductions in QRS\textsubscript{area} (≥45 \text{ μVs}) and QRS\textsubscript{d} against the group with no reductions in either variable. HR indicates hazard ratio.

DOI: 10.1161/JAHA.119.013539
QRS Area and CRT

Okafor et al

statistical means, unobserved variables may have contributed to outcomes. Importantly, vectorcardiographies were derived retrospectively from 12-lead ECGs undertaken before implantation. Inconsistencies in electrode position could conceivably influence vectorcardiography analysis.36 Notwithstanding, all ECGs were acquired by trained cardiac technicians using a standardized operating procedure in routine clinical practice. Consequently, our results should be generalizable to a “real-world” environment. Unfortunately, we did not systematically collect data on device programming. In this respect, variable programming at implantation and follow-up could account for variations in ECG and vectorcardiography variables, as well as outcomes. Although the AUCs for pre-implant QRSarea and ΔQRSarea did not exceed 0.74, these values are comparable to those found in other studies11 and exceed the AUCs for QRSd and LBBB.

Conclusions

Pre-implantation QRSarea was superior to QRSd and QRS morphology in predicting clinical outcomes after CRT. A concomitant reduction in QRSd and QRSarea after CRT was associated with the lowest risk of cardiac and total mortality, as well as ventricular arrhythmias. These findings add support for the use of QRSarea and QRSd in the risk stratification and optimization of CRT recipients.

Sources of Funding

Okafor was supported by an unrestricted educational grant from Medtronic Plc.

Disclosures

None.

References

1. Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronization therapy. J Am Coll Cardiol. 2014;64:1047–1058.
2. Fornwalt BK, Sprague WW, BeDell P, Suerer JD, Gerritte B, Merlino JD, Fyfe DA, Leon AR, Oshinski JN. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation. 2010;121:1985–1991.
3. Auricchio A, Prinzen FW. Enhancing response in the cardiac resynchronization therapy patient: the 3B perspective-bench, bits, and bedside. JACC Clin Electrophysiol. 2017;3:1203–1219.
4. Chung E, Leon A, Tavazzi L, Sun J, Nihoyannopoulos P, Merlino J, Abraham W, Guio S, Leclercq C, Bax J, Yu C-M, Gorcsan J III, Sutton M, De Sutter J, Murillo J. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–2616.
5. Jastrzębski M, Baranchuk A, Fijorek K, Kisiel R, Kukla P, Sondej T, Czarnecka D. Cardiac resynchronization therapy-induced acute shortening of QRS duration predicts long-term mortality only in patients with left bundle branch block. Europace. 2019;21:281–289.
6. Appert L, Menet A, Altes A, Ennatz PV, Bardet-Bouchery H, Binda C, Gyomara Y, Delelis F, Castel AL, Le Goffic C, Guerbaai RA, Graux P, Tribouilloy C, Marechaux S. Clinical significance of electromechanical dys synchrony and QRS narrowing in patients with heart failure receiving cardiac resynchronization therapy. Can J Cardiol. 2019;35:27–33.
7. Mafi R, Mijntjens GW, Engels EB, Bisauw Y, Luermans JG, Pison L, Crijns HJ, Prinzen FW, Vernooij K. Vectorcardiographic QRS area identifies delayed ventricular lateral wall activation determined by electroanatomic mapping in candidates for cardiac resynchronization therapy. Heart Rhythm. 2016;13:217–225.
8. De Pooter JAN, El Haddad M, De Buystere J, Aranda HA, Cornelissen R, Stegemann B, Rinaldi CA, Steilinski M, Sokal A, Francis DP, Jordaus L, Sroogian R, Van Heesewijk F, Timmermans F. Biventricular paced QRS area predicts acute hemodynamic CRT response better than QRS duration or QRS amplitudes. J Cardiovasc Electrophysiol. 2017;28:94–951.
9. Engels EB, Strik M, van Middendorp LB, Kuper M, Vernooij K, Prinzen FW. Prediction of optimal cardiac resynchronization by vectors extracted from electrograms in dysynchronous canine hearts. J Cardiovasc Electrophysiol. 2017;28:94–951.
10. van Deuren C, Vernooij K, Dukin E, Bergfeldt L, Crijns HGM, Prinzen FW, Wecke L. Vectorcardiographic QRS area as a novel predictor of response to cardiac resynchronization therapy. J Electrocardiol. 2015;48:45–52.
11. van Stipdonk AMW, Ter Horst I, Kloosterman M, Engels EB, Rienstra M, Crijns H, Vos MA, van Gelder IC, Prinzen FW, Meine M, Mass AH, Vernooij K. QRS area is a strong determinant of outcome in cardiac resynchronization therapy. Circ Arrhythm Electrophysiol. 2018;11:e006497.
12. Emerek K, Friedman DJ, Sørensen PL, Hansen SM, Larsen JM, Risum N, Thagersen AM, Graf C, Kisslo J, Sgaard P, Atwater BD. Vectorcardiographic QRS area is associated with long-term outcome after cardiac resynchronization therapy. Heart Rhythm. 2018;15:213–219.
13. Lux R, Urie P, Burgess M, Abildskov L. Variability of the body surface distributions of QRS, ST-T and QRS deflection areas with varied activation sequence in dogs. Cardiovasc Res. 1980;14:607–612.
14. National Institute of Health and Care Excellence. NICE technology appraisal [TA 314]: implantable cardioverter defibrillators and cardiac resynchronization therapy for arrhythmias and heart failure (review of TAPS and TA120). 2014. London, United Kingdom. Available at: https://www.nice.org.uk/guidance/ta314. Accessed February 1, 2019.
15. Leyva F, Zegard A, Taylor RJ, Foley PWX, Umar F, Patel K, Panting J, van Dam P, Prinzen FW, Marshall H, Gius T. Long-term outcomes of cardiac resynchronization therapy using apical versus nonapical left ventricular pacing. J Am Heart Assoc. 2018;7:e008508. DOI: 10.1161/JAHA.117.008508.
16. Lindel C, Abraham WT, Gold MR, Daubert C. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (RESynchronization reverSe Modelling in Systolic Left Ventricular Dysfunction) study. J Am Coll Cardiol. 2010;56:1826–1831.
17. Rockman HA, Janeu C, Chatterjee K, Rouleau JL. Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1989;64:1344–1348.
18. Liu X. Classification accuracy and cut point selection. Stat Med. 2012;31:2676–2686.
19. Bristow M, Saxon L, Boehmer J, Krueger S, Kass D, De Marco T, Carson P, DiCarlo L, DeMets D, White B. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
20. Cleland J, Daubert J, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
21. Moss AJ, Hall WJ, Cannon DS, Klein H, Brown MW, Daubert JP, Estes NAM, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338.
22. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannon D, Daubert JP, Elder M, Gold MR, Goldberger JJ, Goldbergen I, Linchstein E, Pitschner H, Rashlan M, Solomon S, Viksin S, Wang P, Moss AJ; MADIT-CRT Investigators. Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation. 2011;123:1061–1072.
23. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol. 2005;46:2183–2192.
24. Bryant AR, Wilton SB, Lai MP, Enver D. Association between QRS duration and outcome with cardiac resynchronization therapy: a systematic review and meta-analysis. J Electrocardiol. 2013;46:147–155.
25. Gold MR, Thebault C, Linde C, Abraham WT, Gerritte B, Ghio S, St John Sutton M, Daubert JC. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Modelling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012;126:822–829.
26. Sweeney MO, van Sommel RJ, Schalij MJ, Borleffs CJ, Hellkamp AS, Bax JJ. Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. Circulation. 2010;121:626–634.

27. Tian Y, Zhang P, Li X, Gao Y, Zhu T, Wang L, Li D, Wang J, Yuan C, Guo J. True complete left bundle branch block morphology strongly predicts good response to cardiac resynchronization therapy. Europace. 2013;15:1499–1506.

28. Bilchick Kenneth C, Kamath S, DiMarco John P, Stukenborg George J. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. 2010;122:2022–2030.

29. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial I: Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395.

30. Bertaglia E, Migliore F, Baritussio A, De Simone A, Reggiani A, Pecora D, D’Onofrio A, Rapacciuolo A, Savarese G, Pierantozzi A, Marenna B, Ruffa F, Campari M, Malacrida M, Stabile G. Stricter criteria for left bundle branch block diagnosis do not improve response to CRT. Pacing Clin Electrophysiol. 2017;40:850–856.

31. Caputo ML, van Stipdonk A, Illner A, D’Ambrosio G, Regoli F, Conte G, Moccetti T, Klersy C, Prinzen FW, Vernooy K, Auricchio A. The definition of left bundle branch block branch block influences the response to cardiac resynchronization therapy. Int J Cardiol. 2018;269:165–169.

32. Kurt S, Makikallio TH, Rautaharju P, Kiviniemi V, Laukkanen JA. Duration of QRS complex in resting electrocardiogram is a predictor of sudden cardiac death in men. Circulation. 2012;125:2588–2594.

33. Morin DP, Oikarinen L, Viitasalo M, Toivonen L, Nieminen MS, Kjeldsen SE, Dahlöf B, John M, Devereux RB, Oxin PM. QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. Eur Heart J. 2009;30:2908–2914.

34. Ploux S, Eschalier R, Whinnett ZI, Lumens J, Derval N, Sacher F, Hocini M, Jais P, Dubois R, Ritter P, Haissaguerre M, Wilkoff BL, Francis DP, Bordachar P. Electrical dyssynchrony induced by biventricular pacing: implications for patient selection and therapy improvement. Heart Rhythm. 2015;12:782–791.

35. Gage RM, Curtin AE, Burns KV, Ghosh S, Gillberg JM, Bank AJ. Changes in electrical dyssynchrony by body surface mapping predict left ventricular remodeling in patients with cardiac resynchronization therapy. Heart Rhythm. 2017;14:392–399.

36. Tomlinson DR, Bashir Y, Betts TR, Rajagop K. Accuracy of manual QRS duration assessment: its importance in patient selection for cardiac resynchronization and implantable cardioverter defibrillator therapy. Europace. 2009;11:638–642.